Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...

The therapy targets mast cells by inhibiting receptor tyrosine kinase KIT, crucial for mast cell function and survival. Significant improvements in UAS7 and quality of life were observed.

Topline data were announced from a phase 3 trial evaluating zanzalintinib in combination with atezolizumab in patients with previously treated non-microsatellite instability (MSI)-high metastatic ...